乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ESMO

<乌鸦传媒>ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer

Adjuvant alectinib reduces disease-free survival hazard by 76%

<乌鸦传媒>Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers

Still some unanswered questions about benefit over other drug regimens, expert says

<乌鸦传媒>Randomized Trial Backs HIF-2a Inhibition in Advanced RCC

After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus

<乌鸦传媒>More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancer

PFS doubled and OS improved, driven by mismatch repair-deficient disease

<乌鸦传媒>Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer

Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy

<乌鸦传媒>Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer

Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care

<乌鸦传媒>New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions

Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses

<乌鸦传媒>'Practice-Changing' Data in Locally Advanced Cervical Cancer

Strategies involving immunotherapy, induction chemo move the needle for first time in decades

<乌鸦传媒>RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC

Two randomized studies demonstrate significantly improved PFS against standard regimens

<乌鸦传媒>Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer

Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy

<乌鸦传媒>Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond

Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation

<乌鸦传媒>Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer

Durvalumab plus olaparib, or alone, paired with chemo boosts PFS in DUO-E trial

<乌鸦传媒>Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years

And early ctDNA reductions correlated with survival

<乌鸦传媒>Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer

But label update planned after potential harm observed in PD-L1-negative subgroup

<乌鸦传媒>Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer

But access, cost, and tolerability may favor the latter option, said researcher

<乌鸦传媒>Potential Practice-Changer for Refractory Metastatic Colon Cancer

Significant survival gain with fruquintinib in patients with heavily pretreated disease

<乌鸦传媒>Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer

"Encouraging activity" with enfortumab vedotin-pembrolizumab in patients with high unmet need

<乌鸦传媒>Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases

However, no benefit seen with short-term hormone therapy versus radiotherapy alone

<乌鸦传媒>Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma

Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy

<乌鸦传媒>KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC

"New second-line standard" in KRAS G12C-mutant disease, says study investigator

<乌鸦传媒>Triplet in First-Line Kidney Cancer Thwarts Disease Progression

Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone

<乌鸦传媒>Survival Bump in Unfit NSCLC With First-Line Immunotherapy

Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets

<乌鸦传媒>Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma

Pathologic complete responses seen in 63% of patients in phase II data

<乌鸦传媒>Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma

Studies appear to contradict benefit previously shown with pembrolizumab in this setting

<乌鸦传媒>Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib

About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists

<乌鸦传媒>'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMO

Preoperative immunotherapy combo in dMMR disease yields major pathologic response in 95%

<乌鸦传媒>Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Option

More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1

<乌鸦传媒>Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancer

Post hoc data point to possible benefit in patients with higher PD-L1 levels

<乌鸦传媒>Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC

Study also shed lights on what may lead to lung cancer in never smokers

<乌鸦传媒>'Potential New Standard' for Progressing Desmoid Tumors

Risk of disease progression or death reduced by 71% with oral gamma secretase inhibitor

<乌鸦传媒>Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer

No clinical benefit boost with anti-CD73 oleclumab added to durvalumab and chemo

<乌鸦传媒>Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials

Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib

<乌鸦传媒>Worse OS With Rucaparib First in Trial of Recurrent, BRCA+ Ovarian Cancer

A closer look at why PARP inhibitor's third-line indication was withdrawn

<乌鸦传媒>Antibody-Drug Conjugate Prolongs Survival in Metastatic Breast Cancer

Positive outcome with sacituzumab govitecan leads to questions about ADC sequencing

<乌鸦传媒>Checkpoint Inhibitors Whiff in Head and Neck Cancer Trials

Avelumab, nivolumab-ipilimumab, pembrolizumab miss endpoints in separate studies

<乌鸦传媒>Survey Says: Support Is Lacking for Cancer's Lingering Effects

Survivors report dissatisfaction with long-term support

<乌鸦传媒>Angiogenesis Inhibitor Slows Extrapancreatic Neuroendocrine Tumors

Almost 7-month increase in median PFS with addition of axitinib to endocrine therapy

<乌鸦传媒>Transarterial Radioembolization Slows Progression of CRC With Liver Mets

Small increase in median PFS when combined with second-line chemotherapy

<乌鸦传媒>Androgen-Targeting Combos Show Promise in Prostate Cancer

Trials extend survival in hormone-sensitive disease

<乌鸦传媒>Bifunctional Protein Shows Promise in HPV-Related Cancers

Objective responses in 28% of pretreated patients, durable in most cases

1